Feryal Clark MP: speeches

Speeches

• 26 Mar 2025 · Motor Neurone Disease · Hansard source

  More

  We work closely with the Department of Health and Social Care to support research into this terrible disease. UK Research and Innovation invested £10 million in MND research in 2023-24, and it also plays a key role in funding the underpinning research that benefits medical research more generally. Since 2022, the Medical Research Council and the National Institute for Health and Care Research have awarded £2.8 million to MND projects led by Scottish research organisations.

• 24 Mar 2025 · BioNTech UK: Financial Assistance · Hansard source

  More

  I beg to move, That this House authorises the Secretary of State to undertake to pay, and to pay by way of financial assistance under section 8 of the Industrial Development Act 1982, a grant or grants exceeding £30 million and up to a total of £129 million to BioNTech UK Limited to support their planned expansion of research and development and artificial intelligence activities in the UK over the next 10 years. It is an honour to serve under your chairmanship, Ms Jardine. This investment comes at an important time for the UK’s thriving life sciences sector, which forms a key pillar of two of the Government’s missions: to kick-start economic growth; and to build an NHS fit for the future. The sector is responsible for over £100 billion of turnover in the UK, and it supports over 304,000 jobs in 6,850 businesses. In addition to supporting our economy, the sector also delivers for patients by providing the medicines and technologies that people need to live longer, healthier lives. As we will set out in the life sciences sector plan, we must build on our world-leading R&D ecosystem and double down on rebuilding an internationally competitive business environment so that innovative companies can start, scale and stay here in the UK. To deliver that plan, we will continue to work in partnership with industry, our life sciences ecosystem and the NHS to seize opportunities that will foster innovation across the UK. To that end, through this proposed grant, we have an opportunity for the UK to secure international investment in innovative, cutting-edge R&D in the face of increasing global competition. As the right hon. and hon. Members present know, BioNTech is an international leader in the biotechnology industry, and the developer of the first licensed mRNA covid-19 vaccine. Building on the vaccine’s success and global impact, BioNTech has applied for a Government grant of £129 million to support its transformation and UK expansion, which will see it invest circa £1 billion over 10 years. Supported by the grant, BioNTech research activities will focus on structural biology, regenerative medicine, oncology and AI-driven drug discovery, spanning three locations and creating about 460 new, directly-employed, highly skilled jobs. In Cambridge, BioNTech will set up a new centre of excellence to focus on drug discovery and development of new treatments for cancer and other serious diseases. That directly supports the Government’s ambition to boost the Oxford-Cambridge growth corridor. In London, BioNTech intends to establish a major hub, including a centre of AI expertise to leverage this game-changing technology and to enhance our understanding of diseases, their causes and drug targeting. At a third site—to be announced shortly—BioNTech plans to undertake R&D into vaccines, including for diseases with high pandemic potential. BioNTech’s decision to invest in the UK and to expand its R&D activities builds on the Government’s existing strategic partnership with the company. That includes BioNTech’s work to provide up to 10,000 NHS patients with personalised immunotherapies by 2030, which is already transforming health outcomes by enabling UK patients to be among the first in the world to benefit from cancer vaccines. That support for BioNTech is further evidence of the Government’s backing of a world-leading life sciences sector. Working together, we are driving growth, creating jobs and fostering innovation that will translate into positive outcomes for patients. Supporting BioNTech’s investment is another signal of our commitment to this crucial sector ahead of launching our ambitious life sciences sector plan in the spring. I commend the motion to the Committee.

• 24 Mar 2025 · BioNTech UK: Financial Assistance · Hansard source

  More

  I thank the Opposition and Liberal Democrat spokespeople. The funding we have discussed today will unlock around £1 billion to further boost the UK’s life sciences sector and, in turn, support the Government’s missions to kick-start economic growth and build an NHS fit for the future. It will also build on our significant progress and commitments to date, including the life sciences innovative manufacturing fund of up to £520 million announced by the Chancellor in October 2024, and our landmark partnerships with Oxford Nanopore and Eli Lilly. The hon. Member for Runnymede and Weybridge (Dr Spencer) commented on the investment environment. I am sure he did not miss the fact that this Government attracted £63 billion-worth of investment at the last international investment summit. We have done the hard work to make that investment a reality. He may be interested to hear that, according to the latest CEO survey by PricewaterhouseCoopers, the UK is the second best country in the world in which to invest. However, we are not complacent, and we are fully committed to making the UK the best place to invest. The life sciences are an area of huge UK expertise, and they are key to that commitment. Securing this investment will send a clear message to innovative companies that the UK is open for business. The hon. Member for Harpenden and Berkhamsted (Victoria Collins) asked about monitoring. The financial assistance will be monitored through the normal procedures used for any investment made by the Government. I am happy to send her details of that process and the timeline for this investment. Working together with industry, this Government are delivering better patient outcomes and driving economic growth. I look forward to continuing that work, and to building on that momentum through the publication and rapid delivery of the life sciences sector plan and industrial strategy in the spring. I commend the motion to the Committee. Question put and agreed to .

• 13 Jan 2025 · Children’s Social Media Accounts · Hansard source

  More

  I will come to that point. On the issue of a ban on smartphones and social media for under-16s, we are focused on building the evidence base to inform any future action. We have launched a research project looking at the links between social media and children’s wellbeing. I heard from the hon. Member for Esher and Walton (Monica Harding) that that needs to come forward and I will pass that on to my colleagues in the Department. My hon. Friend the Member for Lowestoft (Jess Asato) mentioned the private Member’s Bill in the name of my hon. Friend the Member for Whitehaven and Workington (Josh MacAlister). We are aware of his Bill and share his commitment to keeping children safe online. We are aware of the ongoing discussion around children’s social media and smartphone use, and it is important that we allocate sufficient time to properly debate the issue. We are focused on implementing the Online Safety Act and building the evidence base to inform any future action. Of course, we look forward to seeing the detail of my hon. Friend’s proposal and the Government will set out their position on that in line with the parliamentary process. My hon. Friend the Member for Darlington (Lola McEvoy) raised the issue of Ofcom’s ambitions. Ofcom has said that its codes will be iterative, and the Secretary of State’s statement will outline clear objectives for it to require services to improve safety for their users. The hon. Member for Twickenham (Munira Wilson) and my hon. Friend the Member for Bournemouth West (Jessica Toale) mentioned engagement with children, and we know how important that is. Ofcom engaged with thousands of children when developing its codes, and the Children’s Commissioner is a statutory consultee on those codes, but of course we must do more. The hon. Member for Huntingdon (Ben Obese-Jecty) raised the matter of mental health services and our commitment in that regard. He is right that the Government’s manifesto commits to rolling out Young Futures hubs. That national network is expected to bring local services together to deliver support for not only teenagers at risk of being drawn into crime, but those facing mental health challenges, and, where appropriate, to deliver universal youth provision. As he rightly said, that is within the health portfolio, but I am happy to write to him with more detail on where the programme is. We want to empower parents to keep their children safe online. We must also protect children’s right to express themselves freely, and safeguard their dignity and autonomy online.

• 16 Oct 2024 · Life Sciences: Stevenage · Hansard source

  More

  My hon. Friend rightly acknowledges that Stevenage is a leading hub for life sciences companies to develop and commercialise cutting-edge therapeutics. GSK and Airbus are shining examples of UK innovation at work. Earlier this week we published the industrial strategy Green Paper to drive long-term, sustainable, inclusive and secure growth, and to secure investment in crucial sectors of the economy, including life sciences. There is an opportunity to renew the UK’s leadership in life sciences through bold innovation and collective partnerships with the sector, to build an NHS that is fit for the future and to drive economic growth across the regions of the UK.

• 2 Sept 2024 · Technology in Public Services · Hansard source

  More

  I thank my hon. Friend for her contribution. As someone who served in local government for a very long time, I recognise the innovation in our local authorities. The work we are doing within our Department includes working very closely with our local government partners, so I thank her for her intervention. One of the first places I visited in my new brief was Hammersmith hospital, where I met doctors who are using a new AI tool that can spot signs of ageing in the heart that are invisible to the human eye. The tool promises to calculate a person’s “heart age” from an MRI scan and, for the first time, pinpoint the genes that could make the heart age faster. In the process, it could transform the way we diagnose and treat heart failure. That is just one of the projects I saw in Hammersmith hospital that is focused on the safe, ethical and responsible development of AI. Such projects will be a crucial part of our mission to build an NHS that is fit for the future—a mission to which this Government are completely committed. We want to seize every opportunity that technology offers to improve lives for our people—whether that means life-saving healthcare in our hospitals or a world-class education in our classrooms. If used rightly, technologies such as AI can transform the productivity of Britain’s broken services. With a £22 billion black hole in the public finances and taxes at a 70-year high, saving taxpayers’ money is more important than ever.